Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | PDE6D | O43924 | 1/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.58 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884325 | 0.99 | HMGCR (0.61) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL18979238 | 0.95 | HMGCR (0.64) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1740204 | 0.95 | HMGCR (0.64) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1741831 | 0.94 | HMGCR (0.63) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1739611 | 0.94 | HMGCR (0.63) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2684323 | 0.94 | HMGCR (0.63) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Tert-Butylamine SCHEMBL1739621 | 0.92 | HMGCR (0.60) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL17635504 | 0.87 | HMGCR (0.67) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3890153 | 0.86 | HMGCR (0.46) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL6789988 | 0.85 | HMGCR (0.59) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013188-B1 | ROSUVASTATIN ZINC SALT | EGIS GYÓGYSZERGYÁR NYILVÁNOSAN MÚKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) | 2016-09-07 | — | — | EP | claimed |
| US-20090306117-A1 | ROSUVASTATIN ZINC SALT | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2009-12-10 | — | — | US | claimed |
| EP-2013188-A1 | ROSUVASTATIN ZINC SALT | Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) | 2009-01-14 | — | — | EP | claimed |
| WO-2007119085-A1 | ROSUVASTATIN ZINC SALT | EGIS GYÓGYSZERGYÁR NYILVÁNOSAN MUKODO RESZVENYTÁRSASÁG (HU) | 2007-10-25 | — | — | WO | claimed |
| EP-2013188-B1 | ROSUVASTATIN ZINC SALT | EGIS GYÓGYSZERGYÁR NYILVÁNOSAN MÚKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) | 2016-09-07 | — | — | EP | disclosed |
| US-9174945-B2 | Rosuvastatin zinc salt | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2015-11-03 | — | — | US | disclosed |
| US-20090306117-A1 | ROSUVASTATIN ZINC SALT | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2009-12-10 | — | — | US | disclosed |
| EP-2013188-A1 | ROSUVASTATIN ZINC SALT | Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007119085-A1 | ROSUVASTATIN ZINC SALT | EGIS GYÓGYSZERGYÁR NYILVÁNOSAN MUKODO RESZVENYTÁRSASÁG (HU) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306117-A1 | ROSUVASTATIN ZINC SALT | SLC39A11, SLC39A3, SLC30A7 | HMGCR 4/4885ALDH1A1 417/4885CYP3A4 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.